For how we live.
12 articles published between December 3, 2025 and September 22, 2026.
Observational studies tie hearing loss to faster mental decline. But the first large randomised trial found no overall benefit from hearing aids over three years — with a signal of help only in higher-risk older adults.
A landmark trial pushed blood pressure hard and cut mild cognitive impairment — but its headline dementia result fell short of significance after the study stopped early. The pooled trial evidence is real, and modest.
Everyday lapses are a poor guide to trouble. The line that matters is whether memory loss is measurable beyond your age and whether it is starting to affect daily function.
Forgetting a name is not dementia, and a third of people diagnosed with mild cognitive impairment revert to normal. But that diagnosis still carries weight: risk of dementia stays elevated even in those who bounce back.
Two large cohorts link purpose in life to lower mortality and lower Alzheimer's risk. Whether purpose protects health, or health sustains purpose, is what the studies cannot fully separate.
A ten-person phase 1 study measured whether oral rapamycin reaches the central nervous system in early Alzheimer's. It did not — and several disease biomarkers rose over eight weeks.
The link between puzzles and a sharper old age is real in the data and largely the wrong way round: the earliest changes of dementia quietly reduce the very activities that later look protective.
The best long-term trial found trained skills can last a decade. Whether they transfer to daily life, or hold off dementia, is where the evidence — and the FTC — parted ways with the marketing.
In 85 people with mild cognitive impairment, transient beta-band events recorded at rest differed years before diagnosis. The sample is small and the finding has not been replicated.
Pooling ten studies, researchers found menopause hormone therapy neither raised nor lowered dementia risk. The certainty of that evidence ranged from moderate to very low.
A small longitudinal study found reduced spindle activity over the temporal lobes in early Alzheimer's — and that lower temporal spindle density tracked with faster decline over up to seven years.
Semaglutide moved Alzheimer's biomarkers without moving the clinic. A separate liraglutide trial missed its primary endpoint on brain metabolism. Together they close a decade-old hypothesis — or at least narrow it.